Kytopen announced that John Zhao, Director of Process Development, is joining the All-Star Team for the Flowfect Tx Cell Engineering Grant.
Published
Signal category
Presence & Recognition
Quote
“Meet another member of the Kytopen All-Star Team: John Zhao, Director of Process Development.”
— Kytopen team
Company
Kytopen
Open cells to new possibilities: Accelerating cell therapy processes from discovery through manufacturing with Flowfect®
- Industry
- Biotechnology Research
- Location
- Cambridge, US
- Company size
- 26 employees
Kytopen is focused on the development and commercialization of groundbreaking genome engineering platforms for expediting the discovery, development, and manufacture of gene-modified cell therapies. Developed at MIT, the Flowfect® platform, harmonizing microfluidics and automation, revolutionizes the delivery of genome engineering materials to cells of therapeutic interest in an expeditious, scalable, and economically advantageous manner compared to current alternatives. In May 2023, Kytopen unveiled the Flowfect Discover™, an automated high-throughput genome engineering platform, and disclosed strategic partnerships with industry-leading Contract Development and Manufacturing Organizations (CDMOs) and translational academic medical centers. By combining Flowfect Discover™ with the Flowfect Tx™ large-scale delivery device in process development workflows, developers can now surmount manufacturing challenges during the discovery stage, fostering swifter and more cost-effective innovation.
Founded 2017